Search
Diethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedAnd, despite concerns over excessive exposure to the chemical, appropriate usage of the chemical at the recommended dosages and routes of administration have generally proven to be safe - even when most
Papain
go.drugbank.com/drugs/DB11193ApprovedWithdrawnPresent in over-the-counter mixture products consisting of different digestive enzymes, its active site contains a catalytic diad that plays a role in breaking peptide bonds.
Macadamia seed oil glycereth-8 esters
go.drugbank.com/drugs/DB14318InvestigationalMacadamia seed oil glycereth-8 esters is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
PL-3994
go.drugbank.com/drugs/DB15355InvestigationalPL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Vintafolide
go.drugbank.com/drugs/DB05168InvestigationalVintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Mavoglurant
go.drugbank.com/drugs/DB13004InvestigationalMavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
ETC-588
go.drugbank.com/drugs/DB05456ExperimentalETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells ...
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence